One picture to understand Jiuyuan Gene (02566) 2025 annual performance: performance remains resilient, reinvest in research and development to enhance long-term competitiveness.

09:03 31/03/2026

In 2025, Jiuyuan Genetics (02566) achieved a revenue of 1.306 billion yuan and a net profit of 138 million yuan, with a corresponding net profit margin increasing by 0.5 percentage points year-on-year to 10.6%.

In 2025, Jiuyuan Gene (02566) achieved a revenue of 1.306 billion yuan and a net profit of 138 million yuan, with a corresponding net profit margin increasing by 0.5 percentage points to 10.6% year-on-year. While maintaining resilient performance, the company continues to invest in research and development to enhance its long-term competitiveness. Looking ahead, Jiuyuan Gene aims to transition from a strategy of "mimicry and breakthroughs" to "leading innovation and global expansion" while maintaining steady growth in its existing businesses. The company strives to become a leading domestic innovative biopharmaceutical company in the fields of oncology, hematology, orthopedics, and metabolic diseases with international competitiveness.

HK Stock Market Move | BOC Hong Kong (02388) rose more than 5% after the performance announcement. Shareholders' attributable surplus increased by 4.9% year-on-year. The annual dividend increased by 6.8% compared to the previous year.

HK Stock Market Move | GT Gold (08299) rose by more than 31%, proposing to purchase all the shares of Changsheng United Investment for 585 million Hong Kong dollars to strengthen its mineral portfolio.

Chip stocks have fallen as a "cash machine" for risk aversion, with Micron (MU.US) and SK Hynix leading the semiconductor sector's worst single month in three and a half years.